Viral Eye Infections Treatment Guidelines

Introduction to Viral Eye Infections

The American Academy of Ophthalmology recommends using topical ganciclovir 0.15% gel 3-5 times daily or trifluridine 1% solution 5-8 times daily, combined with oral antivirals for optimal outcomes in herpes simplex virus (HSV) conjunctivitis 1, 2
Topical ganciclovir is significantly less toxic to the ocular surface than trifluridine, which inevitably causes epithelial toxicity if used for more than 2 weeks 1, 2

The American Academy of Ophthalmology recommends oral antiviral regimens, including acyclovir 200-400 mg five times daily 1, valacyclovir 500 mg two or three times daily 1, and famciclovir 250 mg twice daily 1, 2, 3
Combination therapy with topical and oral antivirals is essential for optimal outcomes in HSV blepharoconjunctivitis 1, 2

Topical antivirals alone have not been shown to be helpful for VZV conjunctivitis, but may be used as additive treatment in unresponsive patients 1, 2, 3
Topical antibiotics are recommended to prevent secondary bacterial infection as vesicles undergo necrosis before healing 1, 2, 3
Oral antivirals, including acyclovir 800 mg five times daily for 7 days 3, valacyclovir 1000 mg every 8 hours for 7 days 3, and famciclovir 500 mg three times daily for 7 days 1, 2, 3, are the mainstay of treatment for persistent or recalcitrant disease

Off-label topical ganciclovir 0.15% gel has shown potential benefit against specific adenovirus serotypes in research settings, but further large-scale efficacy studies are needed before definitive recommendations 2
Supportive care, including artificial tears for symptomatic relief 2 and topical corticosteroids at minimum effective dose for severe subepithelial infiltrates 2, 4, remains standard

The Centers for Disease Control and Prevention recommends ganciclovir intraocular implant plus oral valganciclovir for preventing relapse in sight-threatening CMV retinitis in HIV/AIDS patients with CD4+ counts <50 cells/µL 5, 6, 7, 8
Oral valganciclovir alone may be adequate for small peripheral lesions 6, 7
Initial intravitreous ganciclovir injection is recommended by some ophthalmologists to deliver high local concentration immediately until implant placement 5, 6, 7

The American Academy of Ophthalmology recommends avoiding topical corticosteroids in HSV epithelial infections as they potentiate HSV infection and should be strictly avoided 1, 2, 3, 4
Contact lens wear is contraindicated during any viral conjunctivitis treatment and when signs/symptoms are present
Neonatal HSV requires urgent systemic evaluation as systemic infection is life-threatening 1, 2
Monitor for complications, including visual acuity measurement and slit-lamp biomicroscopy within 1 week for HSV cases 1, 2, and periodic IOP monitoring and pupillary dilation to evaluate for glaucoma and cataract in patients on prolonged topical corticosteroids 2, 4

The CDC (MMWR Recommendations and Reports) advises that CMV retinitis in immunocompromised patients should be treated with systemic antiviral therapy—either oral valganciclovir or intravenous ganciclovir—and may include intra‑ocular ganciclovir implants to achieve adequate intra‑ocular drug levels. 9, 10